# Jiksak Bioengineering

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jiksak-bioengineering

- Industry: Biotechnology
- Headquarters: Kawasaki, Japan
- Website: www.jiksak.co.jp
- Total disclosed funding: $3.4M
- Latest round: Series B (Aug 29, 2022)
- Investors on record: 4

## About

Based in Kawasaki, Japan, Jiksak Bioengineering Inc. specializes in innovative biotechnological solutions targeting intractable neurological diseases through its proprietary Nerve Organoid™ technology.Jiksak Bioengineering Inc. is focused on developing advanced therapeutic solutions for neurological disorders. Founded in 2017 in Kawasaki, Japan, the company has completed a total of 4 deals. The latest funding round, a Series B, raised JPY 469 million, bringing the total amount raised to JPY 469 million and establishing a company valuation of JPY 2,172.802 million. The founders, Jiro Kawada and Nori Yumoto, have a history in biotechnology innovation.Jiksak Bioengineering, Inc. focuses on advanced biotechnological solutions aimed at addressing intractable neurological diseases. Central to its offerings is the Nerve Organoid™ technology, which facilitates the development of safer nerve conduits that enhance the efficacy of peripheral nerve regeneration and functional restoration. These products are designed to specifically target conditions such as amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases by utilizing proprietary molecules that interact at the neuromuscular junction. The company’s client base primarily includes healthcare institutions, research facilities, and potentially pharmaceutical companies that seek innovative therapies for neurological disorders. Jiksak Bioengineering currently serves markets in Japan, the United States, and select regions in Europe, where the need for advanced treatments for neurological diseases is critical.Jiksak Bioengineering generates revenue through the commercialization of its proprietary technologies and therapeutic solutions, structured primarily as B2B transactions. The company partners with medical research institutions and hospitals to deliver its flagship products, such as those developed under the Nerve Organoid™ brand. These transactions may take the form of direct sales agreements or collaborative partnerships for research and product development. Pricing structures for these services are established on a contractual basis, tailored to the specific needs of each partner, and are designed to reflect the advanced nature and efficacy of the technologies offered. Additionally, the company is involved in drug development collaborations that may generate revenue through milestone payments and royalties associated with successful therapeutic outcomes.Following a successful Series B funding round, where Jiksak Bioengineering Inc. raised JPY 331 million in August 2022, the company plans to utilize these funds to accelerate the development of its medical and pharmaceutical devices. The focus will be on introducing new products aimed at treating neurological disorders, with specific timelines for market entry yet to be disclosed. In addition to enhancing its product line, Jiksak aims to expand its operations into new markets, specifically targeting North America and Western Europe by the end of 2023.

## Funding rounds

- Series B, Aug 29, 2022, $3.4M — ANRI, Cyberdyne, Inc., CEJ Capital, Zeon Corporation

## Investors

- ANRI (https://capitalatlas.ai/funds/anri) — Series B
- Cyberdyne, Inc. — Series B
- CEJ Capital (https://capitalatlas.ai/funds/cej-capital) — Series B
- Zeon Corporation — Series B